KALA BIO, INC. Selling, General and Administrative Expense
KALA BIO, INC. (KALA) reported Selling, General and Administrative Expense of $20.57 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2024-03-29
- KALA BIO, INC. selling, general and administrative expense for the quarter ending 2023-12-31 was $4.62M, a 20.72% decline year-over-year.
- KALA BIO, INC. selling, general and administrative expense for the quarter ending 2023-09-30 was $4.95M, a 48.14% decline year-over-year.
- KALA BIO, INC. selling, general and administrative expense for the quarter ending 2023-06-30 was $4.96M, a 78.11% decline year-over-year.
- KALA BIO, INC. selling, general and administrative expense for the quarter ending 2023-03-31 was $6.03M, a 77.65% decline year-over-year.
- KALA BIO, INC. selling, general and administrative expense for fiscal 2023 was $20.57M, a 68.38% decline from fiscal 2022.
- KALA BIO, INC. selling, general and administrative expense for fiscal 2022 was $65.03M, a 38.10% decline from fiscal 2021.
- KALA BIO, INC. selling, general and administrative expense for fiscal 2021 was $105.06M, a 29.60% increase from fiscal 2020.
- KALA BIO, INC. selling, general and administrative expense for fiscal 2020 was $81.07M, a 24.69% increase from fiscal 2019.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2023-12-31 | $4.62M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $9.57M derived: sum of 2 quarters · filed 2024-03-29 | $14.54M derived: sum of 3 quarters · filed 2024-03-29 | $20.57M 10-K · filed 2024-03-29 |
| 2023-09-30 | $4.95M 10-Q · filed 2023-11-13 | $9.91M derived: sum of 2 quarters · filed 2023-11-13 | $15.94M 10-Q · filed 2023-11-13 | $21.77M derived: sum of 4 quarters · filed 2024-03-29 |
| 2023-06-30 | $4.96M 10-Q · filed 2023-08-04 | $10.99M 10-Q · filed 2023-08-04 | $16.82M derived: sum of 3 quarters · filed 2024-03-29 | $26.37M derived: sum of 4 quarters · filed 2024-03-29 |
| 2023-03-31 | $6.03M 10-Q · filed 2023-05-09 | $11.86M derived: sum of 2 quarters · filed 2024-03-29 | $21.41M derived: sum of 3 quarters · filed 2024-03-29 | $44.08M derived: sum of 4 quarters · filed 2024-03-29 |
| 2022-12-31 | $5.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $15.38M derived: sum of 2 quarters · filed 2024-03-29 | $38.05M derived: sum of 3 quarters · filed 2024-03-29 | $65.03M 10-K · filed 2024-03-29 |
| 2022-09-30 | $9.55M 10-Q · filed 2023-11-13 | $32.22M derived: sum of 2 quarters · filed 2023-11-13 | $59.20M 10-Q · filed 2023-11-13 | $83.23M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $22.67M 10-Q · filed 2023-08-04 | $49.66M 10-Q · filed 2023-08-04 | $73.68M derived: sum of 3 quarters · filed 2023-08-04 | $99.03M derived: sum of 4 quarters · filed 2023-08-04 |
| 2022-03-31 | $26.98M 10-Q · filed 2023-05-09 | $51.01M derived: sum of 2 quarters · filed 2023-05-09 | $76.36M derived: sum of 3 quarters · filed 2023-05-09 | $104.34M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $24.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $49.38M derived: sum of 2 quarters · filed 2023-03-03 | $77.36M derived: sum of 3 quarters · filed 2023-03-03 | $105.06M 10-K · filed 2023-03-03 |
| 2021-09-30 | $25.35M 10-Q · filed 2022-11-08 | $53.34M derived: sum of 2 quarters · filed 2022-11-08 | $81.03M 10-Q · filed 2022-11-08 | $107.50M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $27.99M 10-Q · filed 2022-08-11 | $55.69M 10-Q · filed 2022-08-11 | $82.15M derived: sum of 3 quarters · filed 2022-08-11 | $106.04M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $27.70M 10-Q · filed 2022-05-16 | $54.16M derived: sum of 2 quarters · filed 2022-05-16 | $78.06M derived: sum of 3 quarters · filed 2022-05-16 | $93.36M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $26.47M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $50.36M derived: sum of 2 quarters · filed 2022-03-29 | $65.66M derived: sum of 3 quarters · filed 2022-03-29 | $81.07M 10-K · filed 2022-03-29 |
| 2020-09-30 | $23.89M 10-Q · filed 2021-11-15 | $39.19M derived: sum of 2 quarters · filed 2021-11-15 | $54.60M 10-Q · filed 2021-11-15 | $69.09M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $15.30M 10-Q · filed 2021-08-05 | $30.71M 10-Q · filed 2021-08-05 | $45.20M derived: sum of 3 quarters · filed 2021-08-05 | $60.48M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $15.41M 10-Q · filed 2021-05-05 | $29.90M derived: sum of 2 quarters · filed 2021-05-05 | $45.18M derived: sum of 3 quarters · filed 2021-05-05 | $62.19M derived: sum of 4 quarters · filed 2021-05-05 |
| 2019-12-31 | $14.49M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $29.77M derived: sum of 2 quarters · filed 2021-02-25 | $46.78M derived: sum of 3 quarters · filed 2021-02-25 | $65.02M 10-K · filed 2021-02-25 |
| 2019-09-30 | $15.28M 10-Q · filed 2020-11-05 | $32.29M derived: sum of 2 quarters · filed 2020-11-05 | $50.52M 10-Q · filed 2020-11-05 | $64.85M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $17.01M 10-Q · filed 2020-08-06 | $35.24M 10-Q · filed 2020-08-06 | $49.57M derived: sum of 3 quarters · filed 2020-08-06 | $58.04M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $18.24M 10-Q · filed 2020-05-07 | $32.56M derived: sum of 2 quarters · filed 2020-05-07 | $41.03M derived: sum of 3 quarters · filed 2020-05-07 | $48.19M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $14.33M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-12 | $22.80M derived: sum of 2 quarters · filed 2020-02-12 | $29.95M derived: sum of 3 quarters · filed 2020-02-12 | $35.43M 10-K · filed 2020-02-12 |
| 2018-09-30 | $8.47M 10-Q · filed 2019-11-07 | $15.62M derived: sum of 2 quarters · filed 2019-11-07 | $21.10M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $7.15M 10-Q · filed 2019-08-06 | $12.63M 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | $5.48M 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $10.87M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |